Emil Pot

Emil Pot is the Co-Founder and CEO of Allero Therapeutics, a company focused on developing next-generation immunotherapies for allergic and autoimmune diseases utilizing proprietary SOMIT technology. Emil also engages in business development at Oncode Institute, an independent research organization dedicated to cancer research. Prior experience includes serving as a European Patent Attorney at NLO, where Emil provided specialist intellectual property advice, and as Co-Founder and General Counsel of ActoGeniX N.V., which was successfully acquired by Intrexon Corporation. Emil's career began at VIB, a leading life science research institute, where significant contributions to technology transfer and startup creation were made. Education includes a Master's degree in Dutch Law from the University of Groningen and a qualification as a European Patent Attorney from Delta Patents.